Comparison of Somatostatin Analogue (SA) and Chemotherapy (CT) in Neuroendocrine Tumors (NET) Patients with Ki-67 <= 20%

Authors :: Ozaslan, E.
Koca, S.
Sevinc, A.
Bekir Hacioglu
Ozcelik, M.
Duran, A. O.
Yildiz, Y.
Tanriverdi, O.
Menekse, S.
Aksoy, A.
Elmaci, S.
Uysal, M.
Ciltas, A.
[Ozaslan, E.] Erciyes Univ, Kayseri, Turkey -- [Koca, S.] Marmara Univ, Istanbul, Turkey -- [Sevinc, A.] Gaziantep Univ, Gaziantep, Turkey -- [Hacioglu, B.] Trakya Univ, Edirne, Turkey -- [Ozcelik, M.] Kartal Training & Res Hosp, Istanbul, Turkey -- [Duran, A. O.] Ankara AY Training & Res Hosp, Ankara, Turkey -- [Yildiz, Y.] Izmir KC Training & Res Hosp, Izmir, Turkey -- [Tanriverdi, O.] Mugla Univ, Mugla, Turkey -- [Menekse, S.] Celal Bayar Univ, Manisa, Turkey -- [Aksoy, A.] Elazig Univ, Elazig, Turkey -- [Elmaci, S.] Cumhuriyet Univ, Sivas, Turkey -- [Uysal, M.] Afyon Kocatepe Univ, Afyon, Turkey -- [Ciltas, A.] Gazi Univ, Ankara, Turkey
Source :: Web of Science
Abstract: 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease -- MAR 09-11, 2016 -- Barcelona, SPAIN<br />WOS: 000386481600195<br />…<br />ENETS

Subjects :: NET
health services administration
population characteristics
Ki-67
geographic locations
Somatostatin analogue

Tools